**Femasys Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update**
Femasys Inc., a biomedical innovator focused on women's health, reported its financial results for the fiscal year ended December 31, 2025. The company's sales reached $2.29 million, marking a 40.8% increase compared to $1.63 million in 2024. This growth was primarily driven by the commercialization of FemBloc product sales, which contributed $810,000 to the total revenue. However, the cost of sales also increased by 60.1% to $872,400, reflecting the higher sales volume and the introduction of newly commercialized products.
The company's operating expenses totaled $19.01 million, a slight increase of 0.7% from $18.87 million in the previous year. Research and development expenses decreased by 7.8% to $7.58 million, attributed to reduced clinical costs and commercialization of development products into inventory. Sales and marketing expenses increased by 10.3% to $4.44 million, reflecting the expansion of the commercial team and marketing efforts. General and administrative expenses also saw a rise of 5.1%, reaching $6.65 million, primarily due to increased compensation expenses. The company reported a loss from operations of $17.59 million, a slight decrease from $17.79 million in the prior year.
Other expenses, net, totaled $1.04 million, a 1.6% increase from $1.02 million in 2024. This included interest income, changes in the fair value of the conversion option liability and warrants liabilities, interest expense, and other expenses. The company's net loss for the year was $18.63 million, a slight decrease from $18.82 million in 2024. As of December 31, 2025, Femasys had cash and cash equivalents of $9.27 million.
Looking ahead, Femasys anticipates that its current cash and cash equivalents, along with projected revenues, will sustain operations into the third quarter of 2026. The company is actively pursuing additional funding to support the U.S. development and EU commercialization of its FemBloc product candidate. Femasys is a woman-founded and led company with an expansive, internally created intellectual property portfolio with approximately 228 issued patents globally, in-house chemistry, manufacturing, and controls (CMC) and device manufacturing capabilities and proven ability to develop products with commercialization efforts underway.
About FEMASYS INC
Femasys Inc. develops women’s health solutions, including non-surgical permanent birth control, artificial insemination, and diagnostic devices. Its products serve infertility and contraception markets worldwide, offering minimally invasive, cost-effective alternatives to surgery and traditional treatments. With a strong patent portfolio and regulatory approvals, the company focuses on innovative, in-office medical devices that improve safety, accessibility, and patient satisfaction in reproductive health.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.